Bedtime Chronotherapy with Conventional Hypertension Medications to Target Increased Asleep Blood Pressure Results in Markedly Better Chronoprevention of Cardiovascular and Other Risks than Customary On-awakening Therapy - 06/09/17
, Ramón C. Hermida, PhD b, Diana E. Ayala, MD, MPH, PhD b, Artemio Mojón, PhD b, José R. Fernández, PhD bRésumé |
The bases for bedtime hypertension chronotherapy (BHCT) as superior chronoprevention against cardiovascular disease (CVD) are: (1) correlation between blood pressure (BP) and various risks is greater for ambulatory BP monitoring (ABPM) than office BP measurements (OBPM); (2) asleep BP mean is a better predictor of CVD risk than ABPM awake and 24-hour means and OBPM; and (3) targeting of asleep BP by BHCT with one or more conventional medications versus usual on-awakening therapy better reduces major and total CVD events. BHCT offers the most cost-effective chronoprevention against adverse CVD outcomes in regular and vulnerable renal, diabetic, and resistant hypertensive patients.
Le texte complet de cet article est disponible en PDF.Keywords : Prevention, Cardiovascular risk, Ambulatory blood pressure monitoring, Hypertension chronotherapy, Asleep blood pressure, MAPEC Study, Diabetes, Resistant hypertension
Plan
| Disclosure: The authors have nothing to disclose. |
|
| Sources of Support: The MAPEC Study and subsequent ongoing Hygia Project are independent investigator-promoted trials supported by unrestricted grants from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spanish Government (PI14-00205); Ministerio de Ciencia e Innovación, Spanish Government (SAF2006-6254-FEDER; SAF2009-7028-FEDER); Consellería de Economía e Industria, Xunta de Galicia (09CSA018322PR); European Research Development Fund and Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia (CN2012/251; CN2012/260; GPC2014/078); Atlantic Research Center for Information and Communication Technologies (AtlantTIC); and Vicerrectorado de Investigación, University of Vigo. |
|
| Conflicts of Interest: None of the authors have conflicts of interests to declare. |
Vol 13 - N° 4
P. 775-792 - octobre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
